Get it on Google Play

Radiopharm trial advances to higher dose in HER2+ cancer study

August 20, 2026 7:01 AM EDT Send to a Friend
Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) announced that its Data Safety and Monitoring Committee (DSMC) has recommended advancing its 177Lu-RAD202 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login